Changing the Course of Lyme Disease

About Us

FlightpathTM Biosciences is a biotechnology company developing novel therapeutics for the treatment of tick-borne diseases


Based on results of a comprehensive high-throughput screen to identify maximally-effective antiobiotics againstĀ Borrelia burgdorferi, Flightpath is developing proprietary oral drugs for the treatment of acute and Post Treatment Lyme Disease (PTLD). Our goal is to be the first company in decades to bring at least one new therapy to market for patients with Lyme disease.

Flightpath has received both venture funding from private investors and philanthropic organizations.

We would like to collect information during your visit to help us better understand site use. This data is anonymized, and will not be used for marketing purposes. Read More on our Privacy Policy page. You can withdraw permission at any time or update your privacy settings here. Please choose below to continue.